Cargando…

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment

Overexpression of EPHA2 has been observed in multiple cancers and reported to be associated with poor prognosis. Here, we produced an afucosylated humanized anti-EPHA2 monoclonal antibody (mAb), DS-8895a for cancer treatment. The antibody recognizes the extracellular juxtamembrane region of EPHA2 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Jun, Sue, Mayumi, Yamato, Michiko, Ichikawa, Junya, Ishida, Saori, Shibutani, Tomoko, Kitamura, Michiko, Wada, Teiji, Agatsuma, Toshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137487/ https://www.ncbi.nlm.nih.gov/pubmed/27653549 http://dx.doi.org/10.1080/15384047.2016.1235663

Ejemplares similares

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
por: Shitara, Kohei, et al.
Publicado: (2019)

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
por: Yamato, Michiko, et al.
Publicado: (2022)

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
por: Iwata, Tomomi Nakayama, et al.
Publicado: (2019)

Development of DS‐5573a: A novel afucosylated mAb directed at B7‐H3 with potent antitumor activity
por: Nagase‐Zembutsu, Akiko, et al.
Publicado: (2016)

DS-7080a, a Selective Anti-ROBO4 Antibody, Shows Anti-Angiogenic Efficacy with Distinctly Different Profiles from Anti-VEGF Agents
por: Isumi, Yoshitaka, et al.
Publicado: (2020)

Anti‐ORAI1 antibody DS‐2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T‐cell and mast cell activation
por: Aki, Anri, et al.
Publicado: (2020)

Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
por: Ogitani, Yusuke, et al.
Publicado: (2016)

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021)

Diversity in Infection Specificity between the Bloom-forming Microalga Heterosigma akashiwo and Its dsDNA Virus, Heterosigma akashiwo Virus
por: Funaoka, Yusaku, et al.
Publicado: (2023)

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer
por: Nikas, Ilias, et al.
Publicado: (2022)

EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia
por: Pergaris, Alexandros, et al.
Publicado: (2022)

DS16570511 is a small-molecule inhibitor of the mitochondrial calcium uniporter
por: Kon, Naohiro, et al.
Publicado: (2017)

Associations Between Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Traits and Sociodemographic Characteristics in Japanese Workers
por: Suzuki, Tomoko, et al.
Publicado: (2023)

Release of Esterase from Murine Lymphokine‐activated Killer Cells in Antibody‐dependent Cellular Cytotoxic Reaction
por: Kato, Kazunori, et al.
Publicado: (1991)

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma
por: Offenhäuser, Carolin, et al.
Publicado: (2018)

EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016)

The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies
por: Wang, Yaqi, et al.
Publicado: (2021)

Prenatal and Intrapartum Factors Associated With Infant Temperament: A Systematic Review
por: Takegata, Mizuki, et al.
Publicado: (2021)

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
por: Hatano, Manabu, et al.
Publicado: (2004)

Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)

Efficacy of Superficial Temporal Artery-Middle Cerebral Artery Double Anastomoses in a Patient with Rapidly Progressive Moyamoya Disease: Case Report
por: YOKOSAWA, Michiko, et al.
Publicado: (2014)

Novel [(111)In]In-BnDTPA-EphA2-230-1 Antibody for Single-Photon Emission Computed Tomography Imaging Tracer Targeting of EphA2
por: Furukawa, Takenori, et al.
Publicado: (2023)

Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer
por: Ansuini, Helenia, et al.
Publicado: (2009)

Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus
por: Infantino, Maria, et al.
Publicado: (2021)

A Dimerized HMX1 Inhibits EPHA6/epha4b in Mouse and Zebrafish Retinas
por: Marcelli, Fabienne, et al.
Publicado: (2014)

Enhanced p122RhoGAP/DLC-1 Expression Can Be a Cause of Coronary Spasm
por: Kinjo, Takahiko, et al.
Publicado: (2015)

Species Difference among Experimental Rodents in the Activity and Induction of Cytochrome P‐450 Isozymes for Mutagenic Activation of Carcinogenic Aromatic Amines
por: Degawa, Masakuni, et al.
Publicado: (1990)

Targeting EphA2 in cancer
por: Xiao, Ta, et al.
Publicado: (2020)

Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA
por: Zang, Xinlong, et al.
Publicado: (2016)

A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
por: El Zawily, Amr, et al.
Publicado: (2023)

The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size
por: Zapata-Mercado, Elmer, et al.
Publicado: (2022)

Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
por: Kamoun, Walid, et al.
Publicado: (2020)

Antibody-mediated depletion of CCR10(+)EphA3(+) cells ameliorates fibrosis in IPF
por: Hohmann, Miriam S., et al.
Publicado: (2021)

Central Diabetes Insipidus in Refractory Antineutrophil Cytoplasmic Antibody-associated Vasculitis
por: Ohashi, Keiji, et al.
Publicado: (2017)

Mechanisms of Kidney Injury in Lupus Nephritis – the Role of Anti-dsDNA Antibodies
por: Yung, Susan, et al.
Publicado: (2015)

Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus
por: Fu, Shu Man, et al.
Publicado: (2015)

EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?
por: Cioce, Mario, et al.
Publicado: (2021)

Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2
por: Zhou, Yue, et al.
Publicado: (2015)

Cytological Characteristics of Human Glioma‐infiltrating Lymphocytes Stimulated with Recombinant Interleukin 2 and an Anti‐CD3 Antibody
por: Kikuchi, Teturo, et al.
Publicado: (1991)

Chemiluminescence Immunoassay to Detect Anti‐HTLV‐I Antibodies
por: Kamihira, Shimeru, et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_s1vktm824bttu970vbpli4svi9